# MBrace Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mbrace-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.mbracetrx.com
- Total disclosed funding: $35M
- Latest round: Series B (Apr 5, 2023)
- Investors on record: 5

## About

Founded in 2020 and based in California, US, MBrace Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that focuses on developing antibody-drug conjugates (ADCs) to treat cancer patients. The company was co-founded by Isan Chen (CEO), Renata Pasqualini, and Wadih Arap. In November 2023, MBrace Therapeutics, Inc. raised USD 85 million in Series B funding led by new investor TPG, with participation from other investors Avidity Partners and Cowen Healthcare Investments.

The company develops antibody-drug conjugates for two new cancer targets using human antibodies from the SPARTA methodology. As of November 2023, the company has emerged from stealth mode and is currently in the clinical stage of pharmaceutical development. 

The company plans to use the November 2023 funding to focus on testing its ADC, MBRC-101.

## Funding rounds

- Series B, Apr 5, 2023, $35M — Alta Partners, TPG, Venrock, Avidity Partners Management, Cowen Healthcare Investments

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B
- TPG (https://capitalatlas.ai/funds/tpg) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Avidity Partners Management — Series B
- Cowen Healthcare Investments — Series B